Adial Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADIL research report →
Companywww.adialpharma.com
Adial Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
- CEO
- Cary John Claiborne
- IPO
- 2018
- Employees
- 5
- HQ
- Charlottesville, VA, US
Price Chart
Valuation
- Market Cap
- $2.26M
- P/E
- -0.41
- P/S
- 0.00
- P/B
- 0.87
- EV/EBITDA
- 0.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -162.83%
- ROIC
- -202.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,977,171 · 39.56%
- EPS
- $-11.93 · 32.79%
- Op Income
- $-7,799,462
- FCF YoY
- 6.21%
Performance & Tape
- 52W High
- $19.00
- 52W Low
- $1.31
- 50D MA
- $1.65
- 200D MA
- $5.82
- Beta
- 1.27
- Avg Volume
- 148.41K
Get TickerSpark's AI analysis on ADIL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 7, 26 | Goodman Tony | other | 26,510 |
| Apr 7, 26 | Anderson J. Kermit | other | 9,185 |
| Apr 7, 26 | Schuyler Kevin | other | 9,185 |
| Apr 7, 26 | Shah Vinay | other | 17,325 |
| Apr 7, 26 | Gilliland Robertson H. | other | 9,185 |
| Apr 7, 26 | Claiborne Cary J | other | 37,985 |
| May 29, 25 | Gilliland Robertson H. | other | 28,000 |
| May 29, 25 | Newman James W. Jr. | other | 28,000 |
| May 29, 25 | Shah Vinay | other | 9,000 |
| May 29, 25 | Schuyler Kevin | other | 28,000 |
Our ADIL Coverage
We haven't published any research on ADIL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADIL Report →